[go: up one dir, main page]

AR111202A2 - Formas cristalinas de cortexolona - Google Patents

Formas cristalinas de cortexolona

Info

Publication number
AR111202A2
AR111202A2 ARP180100811A ARP180100811A AR111202A2 AR 111202 A2 AR111202 A2 AR 111202A2 AR P180100811 A ARP180100811 A AR P180100811A AR P180100811 A ARP180100811 A AR P180100811A AR 111202 A2 AR111202 A2 AR 111202A2
Authority
AR
Argentina
Prior art keywords
cortexolona
crystal forms
cortexolone
propionate
forms
Prior art date
Application number
ARP180100811A
Other languages
English (en)
Inventor
Luigi Moro
Mauro Ajani
Original Assignee
Cassiopea Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40278805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111202(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cassiopea Spa filed Critical Cassiopea Spa
Publication of AR111202A2 publication Critical patent/AR111202A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C12P33/005—Degradation of the lateral chains at position 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

La presente se refiere además a formas cristalinas del 17-a-propionato de cortexolona. Reivindicación 1: Forma cristalina IV hidratada del 17-a-propionato de cortexolona, caracterizada porque el valor de DRX es como se muestra en la figura 30.
ARP180100811A 2007-08-03 2018-04-03 Formas cristalinas de cortexolona AR111202A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001616A ITMI20071616A1 (it) 2007-08-03 2007-08-03 Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.

Publications (1)

Publication Number Publication Date
AR111202A2 true AR111202A2 (es) 2019-06-12

Family

ID=40278805

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080103135A AR072235A1 (es) 2007-08-03 2008-07-18 Proceso enzimatico para obtener 17-alfa monoesteres de cortexolona y/o sus 9,11-dehidro derivados
ARP180100810A AR111351A2 (es) 2007-08-03 2018-04-03 FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA
ARP180100811A AR111202A2 (es) 2007-08-03 2018-04-03 Formas cristalinas de cortexolona

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP080103135A AR072235A1 (es) 2007-08-03 2008-07-18 Proceso enzimatico para obtener 17-alfa monoesteres de cortexolona y/o sus 9,11-dehidro derivados
ARP180100810A AR111351A2 (es) 2007-08-03 2018-04-03 FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA

Country Status (28)

Country Link
US (11) US8785427B2 (es)
EP (5) EP2503005B1 (es)
JP (3) JP5646992B2 (es)
KR (1) KR101495192B1 (es)
CN (3) CN104861023B (es)
AR (3) AR072235A1 (es)
AU (1) AU2008285784B2 (es)
BR (1) BRPI0814163A2 (es)
CA (3) CA2691445C (es)
DK (4) DK2503005T3 (es)
ES (4) ES2551910T3 (es)
FI (1) FIC20250037I1 (es)
FR (1) FR25C1053I1 (es)
HR (4) HRP20140421T1 (es)
HU (4) HUE026206T2 (es)
IT (1) ITMI20071616A1 (es)
LT (1) LT2966175T (es)
MX (4) MX363238B (es)
NO (1) NO2025055I1 (es)
NZ (3) NZ600767A (es)
PL (4) PL2503004T3 (es)
PT (4) PT2503004E (es)
RS (4) RS58950B1 (es)
RU (2) RU2482190C2 (es)
SI (4) SI2503004T1 (es)
TR (1) TR201909129T4 (es)
WO (1) WO2009019138A2 (es)
ZA (2) ZA201000587B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
ITMI20132157A1 (it) 2013-12-20 2015-06-21 Cosmo Dermatos Srl Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
CN112028956A (zh) * 2020-09-10 2020-12-04 那路新 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
CN116490512B (zh) * 2020-10-19 2025-09-16 工业化学有限公司 21-(乙酰氧基)-17-(1-丙酰氧基)-孕甾-4-烯-3,20-二酮的制备方法
IT202100008429A1 (it) 2021-04-06 2022-10-06 Farmabios Spa Processo per la preparazione di cortexolone 17α-propionato e sua nuova forma cristallina idrata
CN114410727B (zh) * 2022-01-25 2023-09-19 山东诺明康药物研究院有限公司 一种克拉考特酮的制备方法
CN115073546A (zh) * 2022-06-01 2022-09-20 浙江神洲药业有限公司 一种新型雄激素受体抑制剂的制备方法
CN115466301A (zh) * 2022-08-29 2022-12-13 扬州奥锐特药业有限公司 一种甾体化合物，其晶型a及它们的制备方法和用途
IT202300001929A1 (it) 2023-02-07 2024-08-07 Farmabios Spa Cocristalli di cortexolone 17-propionato e metodi per la loro preparazione
TW202444338A (zh) 2023-04-07 2024-11-16 義大利商卡斯歐皮亞股份公司 克拉司酮與米諾地爾之組合療法
EP4529925A1 (en) 2023-09-26 2025-04-02 Cassiopea S.p.A. Cortexolone-17-alpha- propionate for treating acneiform eruptions
WO2025068281A1 (en) 2023-09-26 2025-04-03 Cassiopea S.P.A. CORTEXOLONE-17α-PROPIONATE FOR TREATING ACNEIFORM ERUPTIONS
WO2025094021A1 (en) * 2023-10-31 2025-05-08 Lupin Limited Stable topical cream formulation of clascoterone
WO2025125508A1 (en) 2023-12-14 2025-06-19 Cassiopea S.P.A. Cortexolone-17αlpha-propionate combinations for treating acne
WO2025149998A1 (en) 2024-01-11 2025-07-17 Glenmark Specialty S.A. Topical composition comprising clascoterone and latanoprost for alopecia
WO2025172818A1 (en) 2024-02-14 2025-08-21 Cassiopea S.P.A. Pyrilutamide combination therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB791771A (en) 1954-07-29 1958-03-12 Merck & Co Inc Steroid compounds
US2985650A (en) 1958-05-28 1961-05-23 Syntex Sa 6alpha-ammonio-derivatives of 11-keto cortical hormones
DE1195748B (de) 1961-06-24 1965-07-01 Vismara Francesco Spa Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
NL6605515A (es) * 1966-04-25 1967-10-26
NL6605514A (es) * 1966-04-25 1967-10-26
US3780177A (en) 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US3733318A (en) 1972-03-23 1973-05-15 Syntex Corp 21-orthoesters of cortical steroids and methods of preparing same
JPS5910799B2 (ja) * 1975-07-15 1984-03-12 大正製薬株式会社 プレグナン系ステロイド １７−エステル類の製法
JPS6040439B2 (ja) 1978-03-29 1985-09-11 大正製薬株式会社 ヒドロコルチゾン誘導体
US4318853A (en) 1980-01-31 1982-03-09 The Upjohn Company 9β,11β-Epoxy-5β-corticoids
GB2109817B (en) 1981-11-18 1985-07-03 Ibm Electrodeposition of chromium
DE3243482A1 (de) 1982-11-22 1984-05-24 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung
DE3402330A1 (de) 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4920216A (en) 1987-05-28 1990-04-24 The Trustees Of Columbia In The City Of New York Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5264428A (en) 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
JPH08135789A (ja) 1994-11-09 1996-05-31 Komatsu Ltd 車両の油圧式駆動装置の変速装置およびその変速制御方法
DE19653730C2 (de) 1996-12-11 1999-06-24 Schering Ag Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern
ES2237841T3 (es) 1997-06-25 2005-08-01 Teijin Limited Derivados de vitamina d3 y remedios para enfermedades respiratorias inflamatorias preparados a partir de ellos.
IL158591A0 (en) * 2001-05-22 2004-05-12 Pfizer Prod Inc Crystal forms of azithromycin
ITMI20011762A1 (it) * 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
TW200305396A (en) 2002-03-27 2003-11-01 Shionogi & Co Cartilage extracellular matrix degradation
EP1525215B1 (de) 2002-08-02 2006-09-06 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
CA2517490A1 (en) 2003-03-05 2004-12-02 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US20050008704A1 (en) 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
JP2008189549A (ja) 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
ITMI20051695A1 (it) * 2005-09-14 2007-03-15 Cosmo Spa Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
ITMI20132157A1 (it) 2013-12-20 2015-06-21 Cosmo Dermatos Srl Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
JP2024106500A (ja) 2023-01-27 2024-08-08 理想科学工業株式会社 画像形成装置
JP2024161998A (ja) 2023-05-09 2024-11-21 トヨタ自動車株式会社 車載機

Also Published As

Publication number Publication date
KR101495192B1 (ko) 2015-02-25
US10166245B2 (en) 2019-01-01
EP2173891A2 (en) 2010-04-14
CA2871025C (en) 2016-05-24
RS58950B1 (sr) 2019-08-30
RU2482190C2 (ru) 2013-05-20
US11938141B2 (en) 2024-03-26
MX2010001256A (es) 2010-05-17
DK2966175T3 (da) 2019-07-01
CA2871025A1 (en) 2009-02-12
PT2503005E (pt) 2015-12-09
HUE044237T2 (hu) 2019-10-28
CA2691445A1 (en) 2009-02-12
US20160326210A1 (en) 2016-11-10
AU2008285784B2 (en) 2014-06-26
FR25C1053I1 (fr) 2026-01-16
JP2010535173A (ja) 2010-11-18
CN103450304B (zh) 2016-05-25
EP2966175B1 (en) 2019-05-08
JP2013163683A (ja) 2013-08-22
WO2009019138A2 (en) 2009-02-12
US20140179654A1 (en) 2014-06-26
US20200155572A1 (en) 2020-05-21
MX2019003639A (es) 2019-06-17
EP2966175A1 (en) 2016-01-13
US12337002B2 (en) 2025-06-24
US20220280531A1 (en) 2022-09-08
HUE026507T2 (hu) 2016-06-28
ITMI20071616A1 (it) 2009-02-04
JP2016014045A (ja) 2016-01-28
PT2966175T (pt) 2019-06-27
SI2966175T1 (sl) 2019-08-30
PT2173891E (pt) 2014-05-19
SI2503005T1 (sl) 2015-12-31
US20160051566A1 (en) 2016-02-25
RS54354B1 (sr) 2016-04-28
SI2173891T1 (sl) 2014-06-30
US10159682B2 (en) 2018-12-25
ZA201100133B (en) 2014-03-26
CA2871039C (en) 2017-11-28
LT2966175T (lt) 2019-08-26
PL2966175T3 (pl) 2019-11-29
AR111351A2 (es) 2019-07-03
CA2871039A1 (en) 2009-02-12
MX363238B (es) 2019-03-15
SI2503004T1 (sl) 2015-12-31
US10716796B2 (en) 2020-07-21
EP3521298A1 (en) 2019-08-07
US20190083511A1 (en) 2019-03-21
US9433628B2 (en) 2016-09-06
NO2025055I1 (no) 2025-12-10
CN104861023A (zh) 2015-08-26
TR201909129T4 (tr) 2019-07-22
HUE026206T2 (hu) 2016-05-30
BRPI0814163A2 (pt) 2015-01-20
RU2599452C2 (ru) 2016-10-10
RU2012113839A (ru) 2013-10-20
EP2503004A1 (en) 2012-09-26
JP5646992B2 (ja) 2014-12-24
EP2503005A3 (en) 2012-10-03
CN101743316A (zh) 2010-06-16
ES2554934T3 (es) 2015-12-28
HRP20140421T1 (hr) 2014-06-06
WO2009019138A3 (en) 2009-10-15
HUS2500052I1 (hu) 2025-12-28
EP2173891B1 (en) 2014-02-12
DK2503004T3 (en) 2015-11-02
CN103450304A (zh) 2013-12-18
HRP20151174T1 (hr) 2015-12-04
PL2503005T3 (pl) 2016-05-31
CN101743316B (zh) 2013-09-04
CA2691445C (en) 2017-11-28
NZ615953A (en) 2015-03-27
US20250387412A1 (en) 2025-12-25
RS54361B1 (sr) 2016-04-28
RS53310B (sr) 2014-10-31
US20160324873A1 (en) 2016-11-10
HRP20191143T1 (hr) 2019-09-20
HRP20151298T1 (hr) 2016-01-01
ZA201000587B (en) 2011-04-28
NZ600767A (en) 2013-11-29
US9486458B2 (en) 2016-11-08
EP2503005B1 (en) 2015-09-02
EP2503005A2 (en) 2012-09-26
KR20100044845A (ko) 2010-04-30
DK2173891T3 (da) 2014-04-28
US8785427B2 (en) 2014-07-22
PT2503004E (pt) 2015-12-09
JP6174645B2 (ja) 2017-08-02
PL2173891T3 (pl) 2014-07-31
PL2503004T3 (pl) 2016-05-31
RU2010107599A (ru) 2011-09-10
CN104861023B (zh) 2017-04-12
EP2503004B1 (en) 2015-09-02
JP6108944B2 (ja) 2017-04-05
ES2462946T3 (es) 2014-05-26
FIC20250037I1 (fi) 2025-12-15
AR072235A1 (es) 2010-08-18
NZ599437A (en) 2013-11-29
US20110092472A1 (en) 2011-04-21
US20230104965A1 (en) 2023-04-06
ES2551910T3 (es) 2015-11-24
DK2503005T3 (en) 2015-11-16
US11207332B2 (en) 2021-12-28
ES2732326T3 (es) 2019-11-21
MX363701B (es) 2019-03-29
US20260000681A1 (en) 2026-01-01
AU2008285784A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
AR111202A2 (es) Formas cristalinas de cortexolona
GT200800018S (es) Diseño de motoneta
GT200900008S (es) Diseño de motocicleta
GT200800067S (es) Motocicleta
GT200800083S (es) Diseño ornamental de botella
GT200900007S (es) Motoneta
GT200800037S (es) Barra de dulce
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
GT200800075S (es) Diseño de embudo
PH12016500250B1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
GT200800068S (es) Carena para motocicleta
GT200800084S (es) Diseño de motocicleta
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
GT200900063S (es) Diseño de control remoto
GT200800038S (es) Contenedor
BR112012013001A2 (pt) formas polimorfas iii e iv de n-benzoil-estaurosporina
GT201000008S (es) Modelo industrial de motocicleta
GT200800026S (es) Modelo industrial de motocicleta
WO2014060471A3 (de) Hohlkammerprofil sowie photovoltaikmodul und verwendung eines reversibel komprimierbaren körpers
GT200800048S (es) Brazalete
GT200700092S (es) Modelo industrial de tinaco
GT200900026S (es) Diseño de motocicleta
GT200800047S (es) Diseño de motocicleta
GT200800041S (es) Diseño de motocicleta
GT200700093S (es) Diseño de motocicleta

Legal Events

Date Code Title Description
FB Suspension of granting procedure